Mirtazapina Flas Bluefish (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Flas Bluefish, is a NaSSA presented as an oral preparation for oral use. It is prescribed for major depressive disorder in adult patients.

GNH USA supplies Mirtazapina Flas Bluefish as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is used in the treatment of depressive disorders, acting on serotonergic and noradrenergic pathways.

- Major depressive disorder: reduces depressive symptoms and improves mood in adults. - Depressive disorder with prominent insomnia: helps alleviate sleep disturbances associated with depression. - Depression in elderly patients: provides symptom relief while offering a favorable side‑effect profile for older adults.

Mirtazapine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness

Serious or Rare Side Effects: - Agranulocytosis - Severe neutropenia - Hepatotoxicity - Seizures - Suicidal thoughts or behavior

When prescribing mirtazapine, clinicians should consider several safety measures.

- Assess psychiatric history: evaluate risk of suicidal ideation before initiating therapy. - Monitor weight and metabolic parameters: watch for significant weight gain or lipid changes. - Review hepatic function: adjust use in patients with liver impairment. - Caution in elderly: increased sensitivity to sedation and falls. - Avoid abrupt discontinuation: taper dose to reduce withdrawal symptoms. - Store at ambient temperature: keep below 25 °C in original container, protect from moisture.

Mirtazapine can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome; discontinue MAOI at least 14 days before. - Strong CYP1A2 inhibitors (e.g., fluvoxamine): may increase mirtazapine plasma levels. - Potent CYP3A4 inhibitors (e.g., ketoconazole): can raise drug concentrations.

Moderate Interactions (Monitor Closely): - CNS depressants (benzodiazepines, alcohol): additive sedation. - Anticholinergic agents: may exacerbate dry mouth and constipation. - Serotonergic agents (SSRIs, SNRIs, tramadol): monitor for serotonin syndrome.